Dasatinib: all 282 studies that test it
Page 2 of 3. Open to participants first (27), then studies with results posted, then the rest; newest registration first within each.
- The Effect of Omeprazole on the Pharmacokinetics of Dasatinib in Healthy SubjectsCompletedNCT00655746Phase 1Results posted
- Study of Oral Dasatinib in Subjects With Myelodysplastic Syndrome (MDS) and Excess Marrow BlastsCompletedNCT00624585Not applicableResults posted
- Trial of Dasatinib (Sprycel®) in Subjects With Hormone-refractory Prostate CancerCompletedNCT00570700Phase 2Results posted
- Dasatinib in Treating Patients With Advanced Lung Cancer That Is No Longer Responding to Erlotinib or GefitinibCompletedNCT00570401Phase 2Results posted
- Dasatinib in Combination With Zoledronic Acid for the Treatment of Breast Cancer With Bone MetastasisCompletedNCT00566618Phase 1/2Results posted
- Phase II Study Evaluating The Safety And Response To Neoadjuvant Dasatinib In Early Stage Non-Small Cell Lung CancerTerminatedNCT00564876Phase 2Results posted
- Dasatinib in Treating Patients With Unresectable or Metastatic Squamous Cell Skin Cancer or RAI Stage 0-I Chronic Lymphocytic LeukemiaCompletedNCT00563290Phase 2Results posted
- Dasatinib in Combination With Revlimid (and Dexamethasone)CompletedNCT00560391Phase 1Results posted
- Safety Study of Dasatinib With Bortezomib (Velcade®) and Dexamethasone for Multiple MyelomaTerminatedNCT00560352Phase 1Results posted
- Dasatinib in Relapsed or Refractory Non-Hodgkin's LymphomaCompletedNCT00550615Phase 1/2Results posted
- Total Therapy Study XVI for Newly Diagnosed Patients With Acute Lymphoblastic LeukemiaCompletedNCT00549848Phase 3Results posted
- Phase II Dasatinib Study in Advanced Breast CancerCompletedNCT00546104Phase 2Results posted
- Dasatinib in Treating Patients With Stage IV Pancreatic CancerTerminatedNCT00544908Phase 2Results posted
- Dasatinib in Polycythemia VeraTerminatedNCT00538980Phase 2Results posted
- Dasatinib in Imatinib Resistant/Intolerant Chinese CML (Chronic and Advanced Phase) SubjectsCompletedNCT00529763Phase 2Results posted
- Dasatinib in Treating Patients With Previously Treated Malignant MesotheliomaCompletedNCT00509041Phase 2Results posted
- Dasatinib in Treating Patients With Recurrent or Metastatic Head and Neck CancerCompletedNCT00507767Phase 2Results posted
- Dasatinib in Treating Patients With Previously Treated Metastatic Colorectal CancerCompletedNCT00504153Phase 2Results posted
- A Study of Dasatinib in Chronic Phase Philadelphia Chromosome Positive Chronic Myeloid LeukemiaCompletedNCT00482703Phase 1/2Results posted
- A Phase III Study of Dasatinib vs Imatinib in Patients With Newly Diagnosed Chronic Phase Chronic Myeloid LeukemiaCompletedNCT00481247Phase 3Results posted
- Dasatinib in Treating Patients With Metastatic Pancreatic CancerCompletedNCT00474812Phase 2Results posted
- Dasatinib in Treating Patients With Relapsed Small Cell Lung CancerCompletedNCT00470054Phase 2Results posted
- Trial of Dasatinib in Advanced SarcomasCompletedNCT00464620Phase 2Results posted
- Dasatinib in Treating Patients With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung CancerCompletedNCT00459342Phase 2Results posted
- Dasatinib in Treating Patients With Advanced Liver Cancer That Cannot Be Removed by SurgeryTerminatedNCT00459108Phase 2Results posted
- Phase I Study of Dasatinib (BMS-354825) and Capecitabine for Women With Advanced Breast CancerCompletedNCT00452673Phase 1Results posted
- Study of Dasatinib and Docetaxel in Metastatic Hormone Refractory Prostate CancerCompletedNCT00439270Phase 1/2Results posted
- Dasatinib in Relapsed Chronic Lymphocytic LeukemiaCompletedNCT00438854Phase 2Results posted
- Dasatinib in Treating Patients With Stage III Melanoma That Cannot Be Removed By Surgery or Stage IV MelanomaCompletedNCT00436605Phase 2Results posted
- A Phase II Study of Dasatinib in the Treatment of Relapsed or Plateau Phase Multiple MyelomaCompletedNCT00429949Phase 2Results posted
- Dasatinib in Treating Patients With Recurrent Glioblastoma Multiforme or GliosarcomaCompletedNCT00423735Phase 2Results posted
- S0622, Dasatinib in Treating Patients With Stage IV Breast Cancer That Has Spread to the BoneCompletedNCT00410813Phase 2Results posted
- Treatment of Adult Ph+ LAL With BMS-354825CompletedNCT00391989Phase 2Results posted
- Combination Chemotherapy and Dasatinib in Treating Participants With Philadelphia Positive or BCR-ABL Positive Acute Lymphoblastic Leukemia.CompletedNCT00390793Phase 2Results posted
- Phase II Study of Dasatinib (BMS-354825) for Androgen-deprived Progressive Prostate CancerCompletedNCT00385580Phase 2Results posted
- Study of Dasatinib (BMS-354825) in Patients With Advanced Estrogen/Progesterone Receptor-positive (ER+/PR+) or Her2/Neu-positive (Her2/Neu+)Breast CancerCompletedNCT00371345Phase 2Results posted
- A Study of Dasatinib (BMS-354825) in Patients With Advanced 'Triple-negative' Breast CancerCompletedNCT00371254Phase 2Results posted
- Therapy of Chronic Lymphocytic Leukemia With Dasatinib (BMS-354825)CompletedNCT00364286Phase 2Results posted
- A Study of Dasatinib vs. High-Dose Imatinib (600 mg) in Patients With Chronic Phase Chronic Myeloid Leukemia (CML) Who Failed to Achieve Complete Cytogenetic Response After 3-18 Months of Imatinib TherapyTerminatedNCT00362466Phase 3Results posted
- Study of Dasatinib (BMS-354825) in Patients With Solid TumorsCompletedNCT00339144Phase 1Results posted
- Study of Dasatinib in Patients With Chronic Phase Chronic Myeloid Leukemia and a Suboptimal Response to ImatinibTerminatedNCT00320190Phase 2Results posted
- Study of Dasatinib in Children and Adolescents With Relapsed or Refractory LeukemiaCompletedNCT00306202Phase 1Results posted
- Dasatinib as Therapy for Myeloproliferative Disorders (MPDs)CompletedNCT00255346Phase 2Results posted
- Dasatinib in Treating Patients With Early Chronic Phase Chronic Myelogenous LeukemiaCompletedNCT00254423Phase 2Results posted
- Advanced Chronic Myelogenous Leukemia (CML) - Follow On: Study of BMS-354825 in Subjects With CMLCompletedNCT00123487Phase 3Results posted
- Chronic Myelogenous Leukemia (CML) - Follow on: Study of BMS-354825 in Subjects With CMLCompletedNCT00123474Phase 3Results posted
- Dasatinib (BMS-354835) Versus Imatinib Mesylate in Subjects With Chronic Myeloid LeukemiaCompletedNCT00103844Phase 2Results posted
- Dasatinib (BMS-354825) in Subjects With Myeloid Blast Phase Chronic Myeloid Leukemia Resistant to or Intolerant of Imatinib MesylateCompletedNCT00101816Phase 2Results posted
- Study of BMS-354825 (Dasatinib) in Patients With Chronic Myeloid Leukemia Who Are Either Resistant or Intolerant to ImatinibCompletedNCT00101660Phase 2Results posted
- Study of Dasatinib (BMS-354825) in Patients With Accelerated Phase Chronic Myeloid LeukemiaCompletedNCT00101647Phase 2Results posted
- Imatinib Mesylate or Dasatinib in Treating Patients With Previously Untreated Chronic Phase Chronic Myelogenous LeukemiaActive, not recruitingNCT00070499Phase 2Results posted
- Fludarabine Phosphate and Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Acute Lymphoblastic Leukemia or Chronic Myelogenous Leukemia That Has Responded to Treatment With Imatinib Mesylate, Dasatinib, or NilotinibCompletedNCT00036738Phase 2Results posted
- Improving Physical Ability and Cellular Senescence Elimination in HIVCompletedNCT07144293Phase 2
- Fortifying Healthy Behaviors, Optimizing Medical Therapies and Enhancing Cognitive Function in Older Adults-pilot StudyCompletedNCT07000734Phase 2
- An Drug-drug Interaction Study to Evaluate the Effects of Omeprazole 40mg on the Pharmacokinetics of SPRYCEL®CompletedNCT06145217Phase 1
- Evaluation of DASATINIB Monotherapy Efficacy in Acute Myeloid Leukemia Patients Refractory to VENETOCLAX-AZACITIDINESuspendedNCT06055621Phase 2
- Senolytics to Improve Osteoporosis TherapyCompletedNCT06018467Phase 2
- Study of Brexucabtagene Autoleucel Plus Dasatinib in Adults With Acute Lymphoblastic LeukemiaActive, not recruitingNCT05993949Phase 1
- Dasatinib Plus Quercetin for Accelerated Aging in Mental DisordersActive, not recruitingNCT05838560Phase 2
- Safety and Impact of Dasatinib on Viral Persistence and Inflammation in People With HIV Under Antiretroviral TreatmentCompletedNCT05780073Phase 2
- Cytochrome P450 Inhibition to Decrease Dosage of Dasatinib for Chronic Myelogenous LeukemiaStatus unknownNCT05638763Phase 2
- Safety, Tolerance and Antiretroviral Activity of Dasatinib: a Pilot Clinical Trial in Patients With Recent HIV-1 InfectionActive, not recruitingNCT05527418Phase 2
- Dasatinib and Quercetin to Treat Fibrotic Non-alcoholic Fatty Liver DiseaseCompletedNCT05506488Phase 1/2
- Clinical Research for Azacitidine Combined With Low-dose Dasatinib in Maintenance Therapy of Acute Myeloid LeukemiaStatus unknownNCT05042531Not applicable
- A Study of TKI Maintenance Therapy Following Allo-HSCT in Newly Diagnosed Ph+ Adult ALLStatus unknownNCT05024357Not applicable
- ASTX727 and Dasatinib for the Treatment of Newly Diagnosed Philadelphia Chromosome or BCR-ABL Positive Chronic Myeloid Leukemia in Chronic PhaseActive, not recruitingNCT05007873Phase 2
- Safety and Effectivness of Quercetin & Dasatinib on Epigenetic AgingStatus unknownNCT04946383Phase 2
- A Study of Dasatinib as First-line Treatment for Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia (CML-CP)CompletedNCT04925141Phase 4
- Venetoclax, Dasatinib, Prednisone, Rituximab and Blinatumomab for the Treatment of Newly Diagnosed or Relapsed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia or Mixed Phenotype Acute LeukemiaActive, not recruitingNCT04872790Phase 1
- Pediatric-Inspired Chemotherapy Plus Tyrosine Kinase Inhibitor in Adult Philadelphia Chromosome-Positive Acute Lymphoblastic LeukemiaWithdrawnNCT04845035Phase 2
- Dasatinib for the Treatment of Moderate and Severe COVID-19WithdrawnNCT04830735Phase 2
- ALSENLITE: Senolytics for Alzheimer's DiseaseActive, not recruitingNCT04785300Phase 1/2
- An Open-Label Intervention Trial to Reduce Senescence and Improve Frailty in Adult Survivors of Childhood CancerActive, not recruitingNCT04733534Phase 2
- Senolytic Therapy to Modulate the Progression of Alzheimer's Disease (SToMP-AD) StudyActive, not recruitingNCT04685590Phase 2
- A Study of REduction And DIscontinuation Treatment of TKI (Imatinib, Nilotinib, Dasatinib and Bosutinib)Status unknownNCT04578847Phase 2
- Testing Dasatinib as a Potential Targeted Treatment in Cancers With DDR2 Genetic Changes (MATCH-Subprotocol X)WithdrawnNCT04439305Phase 2
- PD-1 Combined With Dasatinib for as Third-line Treatment for ARID1A Mutation Advanced NSCLCStatus unknownNCT04284202Phase 2
- Dasatinib for the Prevention of Oxaliplatin-Induced Neuropathy in Patients With Metastatic Gastrointestinal Cancer Receiving FOLFOX Chemotherapy With or Without BevacizumabCompletedNCT04164069Phase 1
- Dose Reduced Dasatinib (70 mg Daily) as First-line Treatment for Newly Diagnosed CML-CPStatus unknownNCT04155411Phase 4
- Efficacy and Safety of TKIs' Withdrawal After a Two-step Dose Reduction in Patients with Chronic Myeloid LeukemiaActive, not recruitingNCT04147533Phase 2
- Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME TrialTerminatedNCT03878524Phase 1
- Low Dose Dasatinib (50 mg Daily) as First-line Treatment for Newly Diagnosed Chronic-Phase Chronic Myeloid LeukemiaCompletedNCT03625388Phase 2
- Persistence of MR3 in Chronic Myeloid Leukemia (CML) After a 2nd Stop of TKI TreatmentStatus unknownNCT03573596Phase 2
- Precision Diagnosis Directing HDACi and TKI Target Therapy for Adult Ph-like ALLStatus unknownNCT03564470Phase 2/3
- Dasatinib Combined With Chemotherapy in Relapsed t(8;21) Acute Myeloid Leukemia With KIT D816 MutationWithdrawnNCT03560908Phase 1
- Pembrolizumab and Dasatinib, Imatinib Mesylate, or Nilotinib in Treating Patients With Chronic Myeloid Leukemia and Persistently Detectable Minimal Residual DiseaseActive, not recruitingNCT03516279Phase 2
- Evaluation of ETC-1907206 With Dasatinib in Advanced Haematologic MalignanciesWithdrawnNCT03414450Phase 1
- Low-dose Dasatinib as First-line Treatment for Chronic Myeloid LeukemiaStatus unknownNCT03216070Phase 4
- KISS Study: Kinase Inhibition With Sprycel Start upActive, not recruitingNCT03193281Phase 2
- The Efficiency of CAMS (Chinese Academy of Medical Sciences)-2016 Trial for Pediatric Acute Myeloid LeukemiaStatus unknownNCT03173612Not applicable
- Total Therapy XVII for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia and LymphomaActive, not recruitingNCT03117751Phase 2/3
- Dasatinib Versus Nilotinib for Treatment Naïve Chronic Myeloid LeukemiaTerminatedNCT03079505Phase 3
- Dasatinib Holiday for Improved TolerabilityCompletedNCT02890784Phase 3
- Dasatinib and Low Intensity Chemotherapy for Ph+ Acute Lymphoblastic LeukemiaCompletedNCT02888990Phase 2
- Targeting Pro-Inflammatory Cells in Idiopathic Pulmonary Fibrosis: a Human TrialCompletedNCT02874989Phase 1
- Study of Pts With Philadelphia Chromosome-Pos ALL With Comb of Ibrutinib, Dasatinib, and PrednisoneWithdrawnNCT02815059Phase 1
- A Clinical Trial Evaluating the Efficacy and Safety of Dasatinib in Refractory Metastatic GISTStatus unknownNCT02776878Not applicable
- D-ALBA Frontline Sequential Dasatinib and Blinatumomab in Adult Philadelphia Positive Acute Lymphoblastic LeukemiaStatus unknownNCT02744768Phase 2
- Low-dose Chemotherapy Combine With Tyrosine Kinase Inhibitor to Treat ph+ Acute Lymphoblastic Leukemia PatientsStatus unknownNCT02690922Phase 4
- Dasatinib and Venetoclax in Treating Patients With Philadelphia Chromosome Positive or BCR-ABL1 Positive Early Chronic Phase Chronic Myelogenous LeukemiaActive, not recruitingNCT02689440Phase 2